ConductScience.org, home

Paper39337463

Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.

Maimaitijiang A and 6 others. Int J Mol Sci, 2024. Cited by 20 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer. Papers, record 39337463. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39337463

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
3.59, provisional
iCite
Revised in PubMed
2024-09-30
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maimaitijiang AAyitila
2He DDongze
3Li DDingyang
4Li WWenfang
5Su ZZhengding
6Fan ZZhongxionghttps://orcid.org/0000-0001-5751-9530
7Li JJinyaohttps://orcid.org/0000-0002-3295-6096

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug Resistance, NeoplasmMajor topic
NeoplasmsMajor topic
Drug Resistance, MultipleMajor topic
Antineoplastic AgentsMajor topic
Humans
Nanoparticles
Drug Delivery Systems
Animals
Nanomedicine

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
(2023D01C202)the Natural Science Foundation of Xinjiang Uygur Autonomous RegionPubMed
(2023B02030-1, 2023B02030-2, and 2023B02030-3)the Key Research and Development Program in the Xinjiang Uygur Autonomous RegionPubMed
(2023TSYCLJ0043)Tianshan Talent Training ProgramPubMed
(XJEDU2023P017)and the Autonomous Region Universities Basic Research Funds Research Projects-Cultivation ProjectsPubMed

Source PubMed

Download CSV of grants

References145

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19822694Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain.J Biol Chem1998https://conductscience.org/library/papers/9822694PubMed
231178121A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.Cell2019https://conductscience.org/library/papers/31178121PubMed
330194528Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.Drug Deliv Transl Res2019https://conductscience.org/library/papers/30194528PubMed
410815920Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.Clin Cancer Res2000https://conductscience.org/library/papers/10815920PubMed
527943612One-Step Microfluidic Synthesis of Nanocomplex with Tunable Rigidity and Acid-Switchable Surface Charge for Overcoming Drug Resistance.Small2017https://conductscience.org/library/papers/27943612PubMed
637855250Multimodal Nanoplatform with ROS Amplification to Overcome Multidrug Resistance in Prostate Cancer via Targeting P-Glycoprotein and Ferroptosis.Adv Healthc Mater2024https://conductscience.org/library/papers/37855250PubMed
736635755Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs.J Nanobiotechnology2023https://conductscience.org/library/papers/36635755PubMed
811747344Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion.Br J Cancer2001https://conductscience.org/library/papers/11747344PubMed
930765258Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.Lancet Oncol2019https://conductscience.org/library/papers/30765258PubMed
1027292613Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.Acta Pharmacol Sin2016https://conductscience.org/library/papers/27292613PubMed
1128123572Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro.Oncol Lett2017https://conductscience.org/library/papers/28123572PubMed
1231561494New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer.Int J Mol Sci2019https://conductscience.org/library/papers/31561494PubMed
1332795847ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells.J Photochem Photobiol B2020https://conductscience.org/library/papers/32795847PubMed
1422761337HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.Cancer Res2012https://conductscience.org/library/papers/22761337PubMed
1527405391Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance.J Biomed Mater Res B Appl Biomater2017https://conductscience.org/library/papers/27405391PubMed
1631245292Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids.Front Oncol2019https://conductscience.org/library/papers/31245292PubMed
1722275822Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.Int J Nanomedicine2012https://conductscience.org/library/papers/22275822PubMed
1833316872Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems.Pharmaceutics2020https://conductscience.org/library/papers/33316872PubMed
1931858458Folate-Gold-Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells.Eur J Drug Metab Pharmacokinet2020https://conductscience.org/library/papers/31858458PubMed
2022448244Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.PLoS One2012https://conductscience.org/library/papers/22448244PubMed

See all 145 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42589703Pro-Apoptotic Organometallic Sn(IV) Bis-Organosilane Benzoate Complexes with Sustained Reduction in Cell Viability Under Resistance-like Conditions in Colorectal Cancer Cells.Int J Mol Sci2026https://conductscience.org/library/papers/42589703PubMed
42488707Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance.MedComm (2020)2026https://conductscience.org/library/papers/42488707PubMed
42388631Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Front Oncol2026https://conductscience.org/library/papers/42388631PubMed
41278192Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors.Front Cell Dev Biol2025https://conductscience.org/library/papers/41278192PubMed
41255464Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.Int J Nanomedicine2025https://conductscience.org/library/papers/41255464PubMed
41182526Re-sensitization of cancer multidrug resistance through P-gp, MRP1 and BCRP modulation: advances in terpenoids based cancer therapy.Discov Oncol2025https://conductscience.org/library/papers/41182526PubMed
40867257Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers (Basel)2025https://conductscience.org/library/papers/40867257PubMed
40574091Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics2025https://conductscience.org/library/papers/40574091PubMed
40573290Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40573290PubMed
40482009Unraveling novel mechanisms of ATP-Binding cassette (ABC) transporter in insulin Resistance-induced amyloidogenesis.Metab Brain Dis2025https://conductscience.org/library/papers/40482009PubMed
39978779Plant-derived extracellular vesicles as nanocarriers for combination therapy enhancing paclitaxel-based regimens in breast cancer.BMB Rep2025https://conductscience.org/library/papers/39978779PubMed
39886464Application of nanomaterials in precision treatment of lung cancer.iScience2025https://conductscience.org/library/papers/39886464PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39337463

GET https://conductscience.org/api/papers/v1/39337463/references?page=2